Considerations on safety and treatment of patients with chronic heart failure at high altitude

Piergiuseppe Agostoni

doi:10.1089/ham.2012.1117

Considerations on safety and treatment of patients with chronic heart failure at high altitude

Piergiuseppe Agostoni

Centro Cardiologico Monzino

Research output: Contribution to journal › Article › peer-review

Abstract

Piergiuseppe Agostoni. Considerations on safety and treatment of patients with chronic heart failure at high altitude. High Alt Med Biol 14:96-100, 2013. - Prognosis and quality of life of chronic heart failure (HF) patients have greatly improved over the last decade. Consequently, many patients are willing to spend leisure time at altitude, usually 1-β₂-α- blocker, reduces the hypoxic ventilatory response through a reduction of the chemoreflex response, and it reduces alveolar-capillary gas diffusion, which is under control by β₂-receptors. These actions are not shared by selective β₁-blockers such as bisoprolol and nebivolol, which should be preferred for treatment of HF patients willing to spend time at altitude. In conclusion, spending time at altitude (

Original language	English
Pages (from-to)	96-100
Number of pages	5
Journal	High Altitude Medicine and Biology
Volume	14
Issue number	2
DOIs	https://doi.org/10.1089/ham.2012.1117
Publication status	Published - Jun 1 2013

ASJC Scopus subject areas

Medicine(all)
Physiology
Public Health, Environmental and Occupational Health

Access to Document

10.1089/ham.2012.1117

Fingerprint Dive into the research topics of 'Considerations on safety and treatment of patients with chronic heart failure at high altitude'. Together they form a unique fingerprint.

Cite this

@article{66ef45e3249d468aad23730bb64a0784,

title = "Considerations on safety and treatment of patients with chronic heart failure at high altitude",

abstract = "Piergiuseppe Agostoni. Considerations on safety and treatment of patients with chronic heart failure at high altitude. High Alt Med Biol 14:96-100, 2013. - Prognosis and quality of life of chronic heart failure (HF) patients have greatly improved over the last decade. Consequently, many patients are willing to spend leisure time at altitude, usually 1-β2-α- blocker, reduces the hypoxic ventilatory response through a reduction of the chemoreflex response, and it reduces alveolar-capillary gas diffusion, which is under control by β2-receptors. These actions are not shared by selective β1-blockers such as bisoprolol and nebivolol, which should be preferred for treatment of HF patients willing to spend time at altitude. In conclusion, spending time at altitude (",

author = "Piergiuseppe Agostoni",

year = "2013",

month = jun,

day = "1",

doi = "10.1089/ham.2012.1117",

language = "English",

volume = "14",

pages = "96--100",

journal = "High Altitude Medicine and Biology",

issn = "1527-0297",

publisher = "Mary Ann Liebert Inc.",

number = "2",

}

TY - JOUR

T1 - Considerations on safety and treatment of patients with chronic heart failure at high altitude

AU - Agostoni, Piergiuseppe

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Piergiuseppe Agostoni. Considerations on safety and treatment of patients with chronic heart failure at high altitude. High Alt Med Biol 14:96-100, 2013. - Prognosis and quality of life of chronic heart failure (HF) patients have greatly improved over the last decade. Consequently, many patients are willing to spend leisure time at altitude, usually 1-β2-α- blocker, reduces the hypoxic ventilatory response through a reduction of the chemoreflex response, and it reduces alveolar-capillary gas diffusion, which is under control by β2-receptors. These actions are not shared by selective β1-blockers such as bisoprolol and nebivolol, which should be preferred for treatment of HF patients willing to spend time at altitude. In conclusion, spending time at altitude (

AB - Piergiuseppe Agostoni. Considerations on safety and treatment of patients with chronic heart failure at high altitude. High Alt Med Biol 14:96-100, 2013. - Prognosis and quality of life of chronic heart failure (HF) patients have greatly improved over the last decade. Consequently, many patients are willing to spend leisure time at altitude, usually 1-β2-α- blocker, reduces the hypoxic ventilatory response through a reduction of the chemoreflex response, and it reduces alveolar-capillary gas diffusion, which is under control by β2-receptors. These actions are not shared by selective β1-blockers such as bisoprolol and nebivolol, which should be preferred for treatment of HF patients willing to spend time at altitude. In conclusion, spending time at altitude (

UR - http://www.scopus.com/inward/record.url?scp=84879627014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879627014&partnerID=8YFLogxK

U2 - 10.1089/ham.2012.1117

DO - 10.1089/ham.2012.1117

M3 - Article

C2 - 23795728

AN - SCOPUS:84879627014

VL - 14

SP - 96

EP - 100

JO - High Altitude Medicine and Biology

JF - High Altitude Medicine and Biology

SN - 1527-0297

IS - 2

ER -